Microbiome therapeutics company Seres Therapeutics (Nasdaq: MCRB) has announced a memorandum of understanding with Nestlé Health Science to sell its Vowst (fecal microbiota spores, live-brpk) assets.
The deal will give Nestlé Health Science full product and intellectual property rights and will enable Seres to pay off debt and focus on the advancement of its other microbiome product candidates.
While financial particulars were not revealed, Seres said it should be able to extend its cash runway into the final quarter of next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze